On July 31, Bayer (BAYRY) said, “Bayer has established additional provisions of around EUR 1.2B for the Roundup litigation. This figure is included in the around EUR 1.7B total mentioned above. In addition to covering defense costs, these additional provisions were mainly attributable to an adverse verdict on the company’s appeal in the Anderson et al. case. The company has taken further legal action against the ruling and filed an application for the case to be transferred to the Missouri Supreme Court for review. Furthermore, the company has achieved a major settlement with a plaintiffs’ law firm, reducing the total number of unresolved glyphosate claims to 61,000. Of the 192,000 claims in total, 131,000 have been settled or are not eligible. Settlements are part of the company’s multi-pronged strategy to significantly contain the US litigation by the end of 2026. For PCBs, Bayer recorded EUR 530M in additional provisions and liabilities for the Burke case, potential future settlements related to the Sky Valley Education Center in the US state of Washington, and other litigation costs. This figure is likewise included in the around EUR 1.7B total mentioned above. Most of the claims alleging personal injury due to PCB exposure relate to the SVEC, a school building in the Seattle area. With respect to the past SVEC verdicts, Bayer continues to await a ruling from the Washington Supreme Court on the Erickson case.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer ‘making headway’ on improving profitability in agricultural business
- Bayer reports Q2 core EPS EUR 1.23 vs. EUR 0.94 last year
- Bayer affirms aim to ‘significantly’ contain litigation risk by end of 2026
- Bayer’s New Study on Sevabertinib: A Potential Game-Changer for Cancer Patients with Liver Impairment
- Bayer’s SMART-Finder Study: A Closer Look at T2DM and Kidney Health